Risk-adapted, MRD-directed Therapy for Young Adults With Newly Diagnosed Acute Myeloid Leukemia
NCT01452646
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
515
Enrollment
OTHER
Sponsor class
Conditions
Acute Myeloid Leukemia
Interventions
OTHER:
Risk-adapted, MRD-directed therapy
Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto